Abstract
The Sandler Center's approach to target-based drug discovery for neglected tropical diseases is to focus on parasite targets that are homologous to human targets being actively investigated in the pharmaceutical industry. In this way we attempt to use both the know-how and actual chemical matter from other drug-development efforts to jump start the discovery process for neglected tropical diseases. Our approach is akin to drug repurposing, except that we seek to repurpose leads rather than drugs. Medicinal chemistry can then be applied to optimize the leads specifically for the desired antiparasitic indication.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
14-alpha Demethylase Inhibitors / chemistry*
-
14-alpha Demethylase Inhibitors / pharmacology
-
Academies and Institutes
-
Binding Sites
-
Crystallography, X-Ray
-
Cysteine Endopeptidases / metabolism
-
Drug Design
-
Drug Evaluation, Preclinical
-
Humans
-
Neglected Diseases / drug therapy*
-
Protease Inhibitors / chemistry*
-
Protease Inhibitors / pharmacology
-
Protease Inhibitors / therapeutic use
-
Protein Kinases / chemistry
-
Protein Kinases / genetics
-
Protein Kinases / metabolism
-
Protozoan Proteins / antagonists & inhibitors
-
Protozoan Proteins / genetics
-
Protozoan Proteins / metabolism
-
RNA Interference
-
Sterol 14-Demethylase / chemistry
-
Sterol 14-Demethylase / metabolism
Substances
-
14-alpha Demethylase Inhibitors
-
Protease Inhibitors
-
Protozoan Proteins
-
Sterol 14-Demethylase
-
Protein Kinases
-
Cysteine Endopeptidases
-
cruzain, Trypanosoma cruzi